Coumarins as cholinesterase inhibitors: A review

Chemico-Biological Interactions

Volumn 254, Issue , 2016, Pages 11-23

  de Souza, Luana G ^a,b   Rennã, Magdalena N ^b   Figueroa Villar, Jose D ^a  

^a MILITARY INSTITUTE OF ENGINEERING   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Benzopyrone; Butyrylcholinesterase; Coumarin; Enzyme inhibition

Indexed keywords

1 (4 FLUOROPHENYL) 3 [4 (6 NITRO 2 OXO 2H CHROMEN 3 YL)THIAZOL 2 YL]UREA; 1 [4 (8 METHOXY 2 OXO 2H CHROMEN 3 YL)THIAZOL 2 YL] 3 (4 CHLOROPHENYL)THIOUREA; 2 OXO N [6 [(1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]HEXYL] 2H CHROMENE 3 CARBOXAMIDE; 2 [4 [2 [(4 METHYL 2 OXO 2H CHROMEN 7 YL)OXY]ETHYL]PIPERAZIN 1 YL]N (1,2,3,4 TETRAHYDROACRIDIN 9 YL)ACETAMIDE; 3 CHLORO 7 HYDROXY 4 METHYLCOUMARIN; 3 [2 [2 (2 BENZYLOXYBENZYLIDENE)HYDRAZINYL]THIAZOL 4 YL] 2H CHROMEN 2 ONE; 3 [2 [2 (3 BROMOBENZYLIDENE) HYDRAZINYL]THIAZOL 4 YL] 2H CHROMEN 2 ONE; 4 [(2 METHOXYPHENYLAMINO)METHYL] 2H BENZOFURO[3,2 G]CHROMEN 2 ONE; 4 [3 (6 BROMO 2 OXO 2H CHROMEN 3 YL) 3 OXOPROP 1 ENYL] 1 (2 FLUOROBENZYL)PYRIDINIUM CHLORIDE; 6 COUMARIN DIAZONIUM; 6 METHYL 4 (4 PHENYLPIPERAZIN 1 YL) 2H CHROMEN 2 ONE; 7 HYDROXY 4 METHYL COUMARIN; 7 HYDROXY 6 [3 (PYRROLIDIN 1 YL)PROPOXY] 2H CHROMEN 2 ONE HYDROCHLORIDE; 7 [3 (CHLOROBENZYL)OXY] 3,4 DIMETHYLCOUMARIN; 8 AMINO 7 (4 FLUOROPHENYL) 9,10,11,12 TETRAHYDROCHROMENO [3',4',5,6] PYRANO [2,3, B]QUINOLIN 6 (7H)ONE; 8 METHOXY 2 OXO 2H CHROMEN 3 CARBOXAMIDE; ACETYLCHOLINESTERASE; AP 2238; AP 2243; CIS 3 (BENZYLAMINO)CYCLOHEXANECARBOXYLIC ACID (6,7 DIMETHOXY 2 OXO 2H CHROMEN 3 YL)AMIDE; COUMARIN DERIVATIVE; HERNIARIN; N (1 BENZYLPIPERIDIN 4 YL) 2 [(2 OXO 2H CHROMEN 7 YL)OXY]ACETAMIDE; N (1 BENZYLPIPERIDIN 4 YL)ACETAMIDE; N1 [2 (1,2,3,4 TETRAHYDROACRIDIN 9 YLAMINO)BUTYL] 2 (7 HYDROXY 2 OXO 2H CHROMEN 4 YL)ACETAMIDE; UMBELLIFERONE; UNCLASSIFIED DRUG; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; PROTEIN BINDING;

CELL DEATH; DRUG BINDING SITE; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HYDROGEN BOND; HYDROLYSIS; HYDROPHOBICITY; IC50; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; ALZHEIMER DISEASE; CHEMISTRY; METABOLISM; SYNTHESIS;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CHOLINESTERASES; COUMARINS; HUMANS; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84977640710     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2016.05.001     Document Type: Review

References (89)

1. [1] Vogel, A., Darftellung von Renzoefäure aus der Tonka-Boline und aus den MeliIoten-oder Steinklee-Blumen. Ann. d. Phyfik 64 (1820), 161–166.
2. [2] Späth, E., Die naturliche cumarine. Berichte, 70, 1937, 83.
3. [3] Harborne, J.B., Plant polyphenols. 2. The coumarins of Solanumpinnatisectum. Biochem. J. 74 (1960), 270–274.
4. [4] Hadacek, F., Muller, C., Werner, A., Greger, H., Proksch, P., Analysis, isolation and insecticidal activity of linear furanocoumarins and other coumarin derivatives fromPeucedanum (Apiaceae: apioideae). J. Chem. Ecol. 20 (1994), 2035–2054.
5. [5] Liu, R., Sun, Q., Sun, A., Cui, J., Isolation and purification of coumarin compounds from Cortex fraxinus by high-speed counter-current chromatography. J. Chrom. A 1072 (2005), 195–199.
6. [6] Spath, E., Pailer, M., Synthese des xanthotoxins. Ber. Dtsch. Chem. Ges., 69, 1936, 767.
7. [7] Harvey, R.G., Cortez, C., Ananthanarayan, T.P., Schmolka, S., A new coumarin synthesis and its utilization for the systhesis of polycyclic coumarin compounds with anticarcinogenic properties. J. Org. Chem. 53 (1988), 3936–3943.
8. [8] Belluti, F., Fontana, G., Bo, L.D., Carenini, N., Giommarelli, C., Zunino, F., Design, synthesis and anticancer activities of stilbene-coumarin hybrid compounds: Identification of novel proapoptotic agents. Bioorg. Med. Chem. 18 (2010), 3543–3550.
9. [9] Tilden, W.A., Burrows, H., The constitution of limettin. J. Chem. Soc., 1902, 508–512.
10. [10] Schmidt, E., Ober das citropten (citronenolstearopten, citronkamfer, citropten,limettin). Arch. Pharm. Ber. 242 (1904), 242–288.
11. [11] Murray, R.D.H., Naturally occurring plant coumarins. Fortschr. Chem. Org. Naturst. 58 (1991), 84–322.
12. [12] Borges, F., Roleira, F., Milhazes, N., Santana, L., Uriarte, E., Simple coumarins and analogues in medicinal chemistry: occurrence, synthesis and biological activity. Cur. Med. Chem. 12 (2005), 887–916.
13. [13] Dean, F.M., Naturally occurring coumarins. Fortschr. Chem. Org. Naturst IX:9 (1952), 225–291.
14. [14] Suttie, J.W., The biochemical basis of warfarin therapy. Adv. Exp. Med. Biol., 1987, 3–16.
15. [15] Ferreira, S.Z., Carneiro, H.C., Lara, H.A., Alves, R.B., Resende, J.M., Synthesis of a new peptide-coumarin conjugate: a potential agent against Cryptococcosis. ACS Med. Chem. Lett. 6 (2015), 271–275.
16. [16] Neyts, J., Cleucq, E., Singha, R., Chang, Y.H., Das, A.R., Chakraborty, S.K., Hong, S.C., Tsay, S.C., Hsu, M.H., Hwu, J.R., Structure-activity relationship of new anti-hepatitis C virus agents: heterobicycle-coumarin conjugates. J. Med. Chem. 52 (2009), 1486–1490.
17. [17] Khan, K.M., Saify, Z.S., Khan, M.Z., Zia-Ullah, Choudhary, M.I., Atta-Ur-Rahman, Perveen, S., Chohan, Z.H., Supuran, C.T., Synthesis of coumarin derivatives with cytotoxic, antibacterial and antifungal activity. J. Enzym. Inhib. Med. Chem. 19 (2004), 373–379.
18. [18] Misra, S., Singh, L.K., Priyanka, Gupta, J., Misra-Bhattacharya, S., Katiyar, D., Synthesis and biological evaluation of 4-oxycoumarin derivatives as a new class of antifilarial agents. Eur. J. Med. Chem. 94 (2015), 211–217.
19. [19] Sashidhara, K.V., Kumar, A., Kumar, M., Sarkar, J., Sinha, S., Synthesis and in vitro evaluation of novel coumarin-chalcone hybrids as potential anticancer agents. Bioorg. Med. Chem. Let. 20 (2010), 7205–7211.
20. [20] Kontogiorgis, C.A., Hadjipavlou-Litina, D.J., Synthesis and anti-inflammatory activity of coumarin derivatives. J. Med. Chem. 48 (2005), 6400–6408.
21. [21] Sashidhara, K.V., Kumar, A., Kumar, M., Srivastava, A., Puri, A., Synthesis and antihyperlipidemic activity of novel coumarinbisindole derivatives. Bioorg. Med. Chem. Lett. 20 (2010), 6504–6507.
22. [22] Kurt, B.Z., Gazioglu, I., Sonmez, F., Kucukislamoglu, M., Synthesis, antioxidant and anticholinesterase activities of novel coumarylthiazole derivatives. Bioorg. Chem. 59 (2015), 80–90.
23. [23] Cortes, N., Alvarez, R., Osorio, E.H., Alzate, F., Berkov, S., Osorio, E., Alkaloid metabolite profiles by GC/MS and acetylcholinesterase inhibitory activities with binding-mode predictions of five Amaryllidaceae plants. J. Pharm. Biomed. Anal. 102 (2015), 222–228.
24. [24] Huang, L., Miao, H., Sun, Y., Meng, F., Li, X., Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer's disease. Eur. J. Med. Chem. 87 (2014), 429–439.
25. [25] Jiang, N., Li, S.Y., Xie, S.S., Li, Z.R., Wang, K.D.G., Wang, X.B., Design, synthesis and evaluation of multifunctional salphen derivatives for the treatment of Alzheimer's disease. Eur. J. Med. Chem. 87 (2014), 540–551.
26. [26] Lahiri, D.K., Farlow, M.R., Greig, N.H., Sambamurti, K., Current drug targets for Alzheimer's disease treatment. Drug Dev. Res. 56 (2002), 267–281.
27. [27] Fukuto, T.R., Mechanism of action of organophosphorus and carbamate insecticides. Environ. Health Persp. 87 (1990), 245–254.
28. [28] Delfino, R.T., Ribeiro, T.S., Figueroa-Villar, J.D., Organophosphorus compounds as chemical warfare agents: a review. J. Braz. Chem. Soc. 20 (2009), 407–428.
29. [29] Martocchia, A., Falaschi, P., Current strategies of therapy in Alzheimer's disease. Open Neuropsychopharm. J. 1 (2008), 19–23.
30. [30] Shah, R.S., Lee, H.G., Xiongwei, Z., Perry, G., Smith, M.A., Castellani, R.J., Current approaches in the treatment of Alzheimer's disease. Biomed. Pharmacother. 62 (2008), 199–207.
31. [31] Mehta, M., Adem, A., Sabbagh, M., New acetylcholinesterase inhibitors for Alzheimer's Disease. Int. J. Alzheimer's Dis. 2012 (2012), 1–8 Article ID 728983.
32. [32] Schneider, L.S., Treatment of Alzheimer's Disease with cholinesterase inhibitors. Clin. Ger. Med. 17 (2001), 337–358.
33. [33] Sugimoto, H., Ogura, H., Arai, Y., Iimura, Y., Yamanishi, Y., Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor. Jpn. J. Pharmacol. 89 (2002), 7–20.
34. [34] Rocha, M.D., Viegas, F.P.D., Campos, H.C., Nicastro, P.C., Fossaluzza, P.C., Fraga, C.A.M., Barreiro, E.J., Junior, C.V., The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders II: Alzheimer's disease. CNS &Neurol. Disord. - Drug Targets 10 (2011), 251–270.
35. [35] Birks, J., Evans, J.G., Iakovidou, V., Tsolaki, M., Rivastigmine for Alzheimer's disease. Cochr. Lib. 2 (2009), 1–193.
36. [36] Rocha, M.D., Viegas, F.P., Campos, H.C., Nicastro, P.C., Fossaluzza, P.C., Fraga, C.A., Barreiro, E.J., Viegas, C. Jr., The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders II: alzheimer's disease. CNS Neurol. Disord. Drug. Targets 10 (2011), 251–270.
37. [37] Fang, L., Kraus, B., Lehmann, J., Heilmann, J., Zhang, Y., Decker, M., Design and synthesis of tacrine–ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates. Bioorg. Med. Chem. Let. 18 (2008), 2905–2909.
38. [38] Engelhart, E., Brucki, S.M.T., Cavalcanti, J.L.S., Forlenza, O.V., Laks, J., Vale, F.A.C., Tratamento da Doença de Alzheimer. Arq. Neuropsiq. 63 (2005), 1104–1112.
39. [39] Sussman, J.L., Harel, M., Frolow, F., Oefner, C., Goldman, A., Toker, L., Silman, I., Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 253 (1991), 872–879.
40. [40] Huang, L., Luo, Z., He, F., Lu, J., Li, X., Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg. Med. Chem. 18 (2010), 4475–4484.
41. [41] Lane, R.M., Potkin, S.G., Enz, A., Targetting acetylcholinesterase and butyrylcholinesterase in dementia. Int. J. Neuropsychopharm 9 (2006), 101–124.
42. [42] Viegas, F.P.D., Simåes, M.C.R., Rocha, M.D., Castelli, M.R., Moreira, M.S., Viegas, C. Jr., Doença de Alzheimer: caracterização, Evolução e Implicaçåes do Processo Neuroinflamatãrio. Rev. Virt. Quim. 3 (2011), 286–306.
43. [43] Bose, D.S., Rudradas, A.P., Babu, M.H., The indium(III) chloride-catalyzed von Pechmann reaction: a simple and effective procedure for the synthesis of 4-substituted coumarins. Tetrahedron Let. 43 (2002), 9195–9197.
44. [44] Ehret-Sabatier, L., Goeldner, M.P., Hirth, C.G., p-Butyroxybenzenediazoniumfluoroborate, substrate of acetyicholinesterase and butyrylcholinesterase, discriminates between the two enzymes by a specific affinity labeling. Biochim. Biophys. Acta 1076 (1991), 137–142.
45. [45] Schalk, I., Ehret-Sabatier, L., Le Feuvre, Y., Bon, S., Massoulie, J., Goeldner, M., 6-Coumarin diazonium salt: a specific affinity label of the Torpedo acetylcholinesterase peripheral site. Mol. Pharm. 48 (1995), 1063–1067.
46. [46] Ellman, G.L., Courtney, K.D., Andres, V. Jr., Featherstone, R.M., A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharm. 7 (1961), 88–95.
47. [47] Simeon-Rudolf, V., Kovarik, Z., Radic, Z., Reiner, E., Reversible inhibition of acetylcholinesterase and butyrylcholinesterase by 4,4%-bipyridine and by a coumarin derivative. Chem. Biol. Interact. 119–120 (1999), 119–128.
48. [48] Radic, Z., Reiner, E., Taylor, P., Role of the peripheral anionic site on acetylcholinesterase: inhibition by substrates and coumarin derivatives. Mol. Pharmacol. 39 (1991), 98–104.
49. [49] Kryger, G., Silman, I., Sussman, J.L., Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Structure 7 (1999), 297–307.
50. [50] Brìhlmann, C., Ooms, F., Carrupt, P.A., Testa, B., Catto, M., Leonetti, F., Altomare, C., Carotti, A., Coumarins derivatives as dual inhibitors of acetylcholinesterase and monoamine oxidase. J. Med. Chem. 44 (2001), 3195–3198.
51. [51] Shen, Q., Peng, Q., Shao, J., Liu, X., Huang, Z., Pu, X., Ma, L., Li, Y.M., Chan, S.C., Gu, L., Synthesis and biological evaluation of functionalized coumarins as acetylcholinesterase inhibitors. Eur. J. Med. Chem. 40 (2005), 1307–1315.
52. [52] Fallarero, A., Oinonen, P., Gupta, S., Blom, P., Galkin, A., Mohan, C.G., Vuorela, P.M., Inhibition of acetylcholinesterase by coumarins: the case of coumarin 106. Pharm. Res. 58 (2008), 215–221.
53. [53] Sethna, S.M., Shah, N.M., The chemistry of coumarins. Chem. Rev. 36 (1945), 1–62.
54. [54] Baker, R.H., Martin, W.B., A side reaction in the Williamson synthesis. II. J. Org. Chem. 25 (1960), 1496–1498.
55. [55] Piazzi, L., Rampa, A., Bisi, A., Gobbi, S., Belluti, F., Cavalli, A., Bartolini, M., Andrisano, V., Valenti, P., Recanatini, M., 3-(4-{[Benzyl(methyl)amino]methyl}-phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced â-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. J. Med. Chem. 46 (2003), 2279–2282.
56. [56] Piazzi, L., Cavalli, A., Belluti, F., Bisi, A., Gobbi, S., Rizzo, S., Bartolini, M., Andrisano, V., Recanatini, M., Rampa, A., Extensive SAR and computational studies of 3-{4-[(Benzylmethylamino)methyl]phenyl}-6,7-dimethoxy-2H-2-chromenone (AP2238) derivatives. J. Med. Chem. 50 (2007), 4250–4254.
57. [57] Piazzi, L., Cavalli, A., Colizzi, F., Belluti, F., Bartolini, M., Mancini, F., Recanatini, M., Andrisano, V., Rampa, A., Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorg. Med. Chem. Let. 18 (2008), 423–426.
58. [58] Leonetti, F., Catto, M., Nicolotti, O., Pisani, L., Cappa, A., Stefanachi, A., Carotti, A., Homo- and hetero-bivalent edrophonium-like ammonium salts as highly potent, dual binding site AChE inhibitors. Bioorg. Med. Chem. 16 (2008), 7450–7456.
59. [59] Zhou, X., Wang, X.B., Wang, T., Kong, L.Y., Design, synthesis, and acetylcholinesterase inhibitory activity of novel coumarin analogues. Bioorg. Med. Chem. 16 (2008), 8011–8021.
60. [60] Bolognesi, M.L., Bartolini, M., Tarozzi, A., Morroni, F., Lizzi, F., Milelli, A., Minarini, A., Rosini, M., Hrelia, P., Andrisano, V., Melchiorre, C., Multitargeted drugs discovery: balancing anti-amyloid and anticholinesterase capacity in a single chemical entity. Bioorg. Med. Chem. Lett. 23 (2013), 2614–2618.
61. [61] Bag, S., Ghosh, S., Tulsan, R., Sood, A., Zhou, W., Schifone, C., Foster, M., LeVine, H. III, Tæræk, B., Tæræk, M., Design, synthesis and biological activity of multifunctional α,β-unsaturated carbonyl scaffolds for Alzheimer's disease. Bioorg. Med. Chem. Let. 23 (2013), 2614–2618.
62. [62] Alipour, M., Khoobi, M., Foroumadi, A., Nadri, H., Moradi, A., Sakhteman, A., Ghandi, M., Shafiee, A., Novel coumarin derivatives bearing N-benzyl pyridinium moiety: potent and dual binding site acetylcholinesterase inhibitors. Bioorg. Med. Chem. 20 (2012), 7214–7222.
63. [63] Raza, R., Saeed, A., Arif, M., Mahmood, S., Muddassar, M., Raza, A., Iqbal, J., Synthesis and biological evaluation of 3-thiazolocoumarinyl schiff-base derivatives as cholinesterase inhibitors. Chem. Biol. Drug. Des. 80 (2012), 605–615.
64. [64] Anand, P., Singh, B., Synthesis and evaluation of substituted 4-methyl-2-oxo-2H-chromen-7-yl phenyl carbamates as potent acetylcholinesterase inhibitors and anti- amnestic agents. Med. Chem. 9 (2013), 694–702.
65. [65] Asadipour, A., Alipour, M., Jafari, M., Khoobi, M., Emami, S., Nadri, H., Sakhteman, A., Moradi, A., Sheibani, V., Moghadam, F.H., Shafiee, A., Foroumadi, A., Novel coumarin-3-carboxamides bearing N-benzylpiperidine moiety as potent acetylcholinesterase inhibitors. Eur. J. Med. Chem. 70 (2013), 623–630.
66. [66] Khoobi, M., Alipour, M., Moradi, A., Sakhteman, A., Nadri, H., Razavi, S.F., Ghandi, M., Foroumadi, A., Shafiee, A., Design, synthesis, docking study and biological evaluation of some novel tetrahydrochromeno [3′,4′:5,6]pyrano[2,3-b]quinolin-6(7H)-one derivatives against acetyl- and butyrylcholinesterase. Eur. J. Med. Chem. 68 (2013), 291–300.
67. [67] Catto, M., Pisani, L., Leonetti, F., Nicolotti, O., Pesce, P., Stefanachi, A., Cellamare, S., Carotti, A., Design, synthesis and biological evaluation of coumarinalkylamines as potent and selective dual binding site inhibitors of acetylcholinesterase. Bioorg. Med. Chem. 21 (2013), 146–152.
68. [68] Silva, J.I., Moraes, M.C., Vieira, L.C.C., Correa, A.G., Cass, Q.B., Cardoso, C.L., Acetylcholinesterase capillary enzyme reactor for screening and characterization of selective inhibitors. J. Pharm. Biomed. Anal. 73 (2013), 44–52.
69. [69] Khoobi, M., Alipour, M., Sakhteman, A., Nadri, H., Moradi, A., Ghandi, M., Emami, S., Foroumadi, A., Shafiee, A., Design, synthesis, biological evaluation and docking study of 5-oxo- 4,5-dihydropyrano[3,2-c]chromene derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors. Eur. J. Med. Chem. 68 (2013), 260–269.
70. [70] Razavi, S.F., Khoobi, M., Nadri, H., Sakhteman, A., Moradi, A., Emami, S., Foroumadi, A., Shafiee, A., Synthesis and evaluation of 4-substituted coumarins as novel acetylcholinesterase inhibitors. Eur. J. Med. Chem. 6 (2013), 252–259.
71. [71] Alipour, M., Khoobi, M., Moradi, A., Nadri, H., Moghadam, F.H., Emami, S., Hasanpour, Z., Foroumadi, A., Shafiee, A., Synthesis and anti-cholinesterase activity of new 7-hydroxycoumarin derivatives. Eur. J. Med. Chem. 82 (2014), 536–544.
72. [72] Nam, S.O., Park, D.H., Lee, Y.H., Ryu, J.H., Lee, Y.S., Synthesis of aminoalkyl-substituted coumarin derivatives as acetylcholinesterase inhibitors. Bioorg. Med. Chem. 22 (2014), 1262–1267.
73. [73] Tasso, B., Catto, M., Nicolotti, O., Novelli, F., Tonelli, M., Giangreco, I., Pisani, L., Sparatore, A., Boido, V., Carotti, A., Sparatore, F., Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease. Eur. J. Med. Chem. 46 (2011), 2170–2184.
74. [74] Kurt, B.Z., Gazioglu, I., Sonmez, F., Kucukislamoglu, M., Synthesis, antioxidant and anticholinesterase activities of novel coumarylthiazole derivatives. Bioorg. Chem. 59 (2015), 80–90.
75. [75] Xie, S.S., Wang, X.B., Li, J.Y., Yang, L., Kong, L.Y., Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease. Eur. J. Med. Chem. 64 (2013), 540–553.
76. [76] Sun, Q., Peng, D.Y., Yang, S.G., Zhu, X.L., Yang, W.C., Yang, G.F., Syntheses of coumarin–tacrine hybrids as dual-site acetylcholinesterase inhibitors and their activity against butylcholinesterase, Aβ aggregation, and b-secretase. Bioorg. Med. Chem. 22 (2014), 4784–4791.
77. [77] Hamulakova, S., Janovec, L., Hrabinova, M., Spilovska, K., Korabecny, J., Kristian, P., Kuca, K., Imrich, J., synthesis and biological evaluation of novel tacrine derivatives and Tacrine−Coumarin hybrids as cholinesterase inhibitors. J. Med. Chem. 57 (2014), 7073–7084.
78. [78] Newman, D.J., Cragg, G.M., Snader, K.M., Natural Products as sources of new drugs over the period 1981–2002. J. Nat. Prod. 66 (2003), 1022–1037.
79. [79] Loizzo, M.R., Tundis, R., Menichini, F., Menichini, F., Natural products and their derivatives as cholinesterase inhibitors in the treatment of neurodegenerative disorders: an update. C. Med. Chem. 15 (2008), 1209–1228.
80. [80] Rollinger, J.M., Hornick, A., Langer, T., Stuppner, H., Prast, H., Acetylcholinesterase inhibitory activity of scopolin and scopoletin discovered by virtual screening of natural products. J. Med. Chem. 47 (2004), 6248–6254.
81. [81] Urbain, A., Marston, A., Hostettmann, K., Coumarins from Peucedanumostruthium as inhibitors of acetylcholinesterase. Pharm. Biol. 43 (2005), 647–650.
82. [82] Salem, S.B., Jabrane, A., Harzallah-Skhiri, F., Jannet, H.B., New bioactive dihydrofuranocoumarins from the roots of the tunisian Ferula lutea (Poir.) maire. Bioorg. Med. Chem. Let. 23 (2013), 4248–4252.
83. [83] Carmichael, J., DeGraff, W.G., Gazdar, A.F., Minna, J.D., Mitchell, J.B., Evaluation of a tetrazolium-based SemiautomatedColorimetrie assay: assessment of chemosensitivity testing. Cancer Res. 47 (1987), 936–942.
84. [84] Dincel, D., Hatipoglu, S.D., Gæren, A.C., Topçu, G., Anticholinesterase furocoumarins from heracleumplatytaenium, a species endemic to the Ida mountains. Turk. J. Chem. 37 (2013), 675–683.
85. [85] Awang, K., Chan, G., Litaudon, M., Ismail, N.H., Martin, M.T., Gueritte, F., 4-Phenylcoumarins from Mesuaelegans with acetylcholinesterase inhibitory activity. Bioorg. Med. Chem. 18 (2010), 7873–7877.
86. [86] Ambure, P., Kar, S., Roy, K., Pharmacophore mapping-based virtual screening followed by molecular docking studies in search of potential acetylcholinesterase inhibitors as anti-Alzheimer's agents. BioSystems 116 (2014), 10–20.
87. [87] Lipinski, C.A., Drug-like properties and the causes of poor solubility and poorpermeability. J. Pharmacol. Toxicol. Methods 44 (2000), 235–249.
88. [88] Kang, S.Y., Lee, K.Y., Park, M.J., Kim, Y.C., Markelonis, G.J., Oh, T.H., Kima, Y.C., Decursin from Angelica gigas mitigates amnesia induced by scopolamine in mice. Neurobiol. Learn. Mem. 79 (2003), 11–18.
89. [89] Kim, D.H., Kim, D.Y., Kim, Y.C., Jung, J.W., Lee, S., Yoon, B.H., Cheong, J.H., Kim, Y.S., Kang, S.S., Ko, K.H., Ryu, J.H., Nodakenin, a coumarin compound, ameliorates scopolamine-induced memory disruption in mice. Life Sci. 80 (2007), 1944–1950.